medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2014, Number 6

<< Back Next >>

Rev Invest Clin 2014; 66 (6)

Cáncer de mama en mujeres jóvenes en México: necesidades y retos clínicos

Villarreal-Garza C, Águila C, Platas A, Lara-Guerra H

Language: Spanish
References: 93
Page: 547-558
PDF size: 157.54 Kb.


Text Extraction

No abstract.


REFERENCES

  1. Knaul FM, Nigenda G, Lozano R, Arreola-Ornelas H, Langer A, Frenk J. Breast cancer in Mexico: a pressing priority. Reprod Health Matters 2008; 16(32): 113-23.

  2. Rodriguez-Cuevas S, Guisa-Hohenstein F, Labastida-Almendaro S. First breast cancer mammography screening program in Mexico: initial results 2005-2006. Breast J 2009; 15(6): 623- 31.

  3. Lara-Medina F, Perez-Sanchez V, Saavedra-Perez D, et al. Triple- negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity. Cancer 2011; 117(16): 3658-69.

  4. Weitzel JN, Blazer KR, Macdonald DJ, Culver JO, Offit K. Genetics, genomics, and cancer risk assessment: State of the Art and Future Directions in the Era of Personalized Medicine. CA Cancer J Clin 2011; 61(5): 327-59.

  5. Rodríguez-Cuevas S, Macias Martinez CG, Labastida Almendaro S. Breast cancer in Mexico. Is it a young women disease? Ginecol Obstet Mex 2000; 68(5): 185-90.

  6. Arce-Salinas C, Lara-Medina FU, Alvarado-Miranda A, et al. Evaluation of breast cancer treatment at a tertiary-level institution with Popular Health Insurance in Mexico. Rev Invest Clin 2012; 64(1): 9-16.

  7. Villarreal-Garza C, Aguila C, Magallanes-Hoyos MC, et al. Breast cancer in young women in Latin America: an unmet, growing burden. Oncologist 2013; 18(Suppl.): 26-34.

  8. Partridge AH, Ruddy KJ, Kennedy J, Winer EP. Model program to improve care for a unique cancer population: young women with breast cancer. J Oncol Pract 2012; 8(5): e105- e110.

  9. Ali A, Warner E. pynk: Breast Cancer Program for Young Women. Curr Oncol 2013; 20(1): e34-e39.

  10. Gabriel CA, Domchek SM. Breast cancer in young women. Breast Cancer Res 2010; 12(5): 212.

  11. Ghiasvand R, Adami HO, Harirchi I, Akrami R, Zendehdel K. Higher incidence of premenopausal breast cancer in less developed countries; myth or truth? BMC Cancer 2014; 14(343): 1-8.

  12. López-Carrillo L. Breast cancer: Age at diagnosis patterns in Latin America and Caribbean. 2013: http://www. salud publica. uchile. cl/salud global_2013/es/ Simposios_simultaneos/La_lucha_global_contra_el_cancer/ Lizbeth_Lopez.pdf.

  13. Kalager M, Adami HO, Bretthauer M, Tamimi RM. Overdiagnosis of invasive breast cancer due to mammography screening: results from the Norwegian screening program. Ann Intern Med 2012; 156(7): 491-9.

  14. dos Santos Silva I, Swerdlow AJ. Recent trends in incidence of and mortality from breast, ovarian and endometrial cancers in England and Wales and their relation to changing fertility and oral contraceptive use. Br J Cancer 1995; 72(2): 485-92.

  15. Chia KS, Reilly M, Tan CS, et al. Profound changes in breast cancer incidence may reflect changes into a Westernized lifestyle: a comparative population-based study in Singapore and Sweden. Int J Cancer 2005; 113(2): 302-06.

  16. Adami HO, Malker B, Holmberg L, Persson I, Stone B. The relation between survival and age at diagnosis in breast cancer. N Engl J Med 1986; 315(9): 559-63.

  17. Love RR, Duc NB, Dinh NV, Quy TT, Xin Y, Havighurst TC. Young age as an adverse prognostic factor in premenopausal women with operable breast cancer. Clin Breast Cancer 2002; 2(4): 294-8.

  18. Gnerlich JL, Deshpande AD, Jeffe DB, Sweet A, White N, Margenthaler JA. Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease. J Am Coll Surg 2009; 208(3): 341-7.

  19. Keegan TH, DeRouen MC, Press DJ, Kurian AW, Clarke CA. Occurrence of breast cancer subtypes in adolescent and young adult women. Breast Cancer Res 2012; 14(2): R55.

  20. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population- based study from the California cancer Registry. Cancer 2007; 109(9): 1721-8.

  21. Walker RA, Lees E, Webb MB, Dearing SJ. Breast carcinomas occurring in young women (< 35 years) are different. Br J Cancer 1996; 74(11): 1796-800.

  22. Anders CK, Hsu DS, Broadwater G, et al. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 2008; 26(20): 3324-30.

  23. Xiong Q, Valero V, Kau V, et al. Female patients with breast carcinoma age 30 years and younger have a poor prognosis: the M.D. Anderson Cancer Center experience. Cancer 2001; 92(10): 2523-8.

  24. Villarreal-Garza CM, Hoyos CM, Meza-Herrera V, et al. Abstract P5-12-10: Pathological characteristics and patterns of recurrence and mortality among young Mexican breast cancer patients. Cancer Research 2013; 73(24 Supplement U). Disponible en: http://cancerres.aacrjournals.org/content/73/24_Supplement/ P5-12-10.abstract):P5-12-10.

  25. Robles-Castillo J, Ruvalcaba-Limon E, Maffuz A, Rodriguez- Cuevas S. Breast cancer in Mexican women under 40. Ginecol Obstet Mex 2011; 79(8): 482-8.

  26. Kroman N, Jensen MB, Wohlfahrt J, Mouridsen HT, Andersen PK, Melbye M. Factors influencing the effect of age on prognosis in breast cancer: population based study. BMJ 2000; 320(7233): 474-8.

  27. Beadle BM, Woodward WA, Tucker SL, et al. Ten-year recurrence rates in young women with breast cancer by locoregional treatment approach. Int J Radiat Oncol Biol Phys 2009; 73(3): 734-44.

  28. Partridge AH, Ruddy KJ. Fertility and adjuvant treatment in young women with breast cancer. Breast 2007; 16(Suppl. 2): S175-S181.

  29. Fobair P, Stewart SL, Chang S, D’Onofrio C, Banks PJ, Bloom JR. Body image and sexual problems in young women with breast cancer. Psychooncology 2006; 15(7): 579-94.

  30. Avis NE, Crawford S, Manuel J. Quality of life among younger women with breast cancer. J Clin Oncol 2005; 23(15): 3322- 30.

  31. Vidal-Millan S, Taja-Chayeb L, Gutierrez-Hernandez O, et al. Mutational analysis of BRCA1 and BRCA2 genes in Mexican breast cancer patients. Eur J Gynaecol Oncol 2009; 30(5): 527- 30.

  32. Calderon-Garciduenas AL, Ruiz-Flores P, Cerda-Flores RM, Barrera-Saldana HA. Clinical follow up of mexican women with early onset of breast cancer and mutations in the BRCA1 and BRCA2 genes. Sal Pub Mex 2005; 47(2): 110-5.

  33. Vaca-Paniagua F, Alvarez-Gomez RM, Fragoso-Ontiveros V, et al. Full-exon pyrosequencing screening of BRCA germline mutations in Mexican women with inherited breast and ovarian cancer. PLoS One 2012; 7(5): e37432.

  34. Weitzel JN, DeHart JNC, Ogaz RM, et al. Prevalence and ancestral origin of BRCA mutations in the Hispanic population: Insights for ancestry-informed genetic cancer risk assessment. ASCO Meeting Abstracts 2011; 29(15 Suppl U). Disponible en: http://meeting.ascopubs.org/cgi/content/abstract/29/15_suppl/ 1514):1514.

  35. Weitzel JN, Clague J, Martir-Negron A, et al. Prevalence and type of BRCA mutations in Hispanics undergoing genetic cancer risk assessment in the southwestern United States: a report from the Clinical Cancer Genetics Community Research Network. J Clin Oncol 2013; 31(2): 210-6.

  36. de la Hoya M, Gutierrez-Enriquez S, Velasco E, et al. Genomic rearrangements at the BRCA1 locus in Spanish families with breast/ovarian cancer. Clin Chem 2006; 52(8): 1480-5.

  37. Torres D, Rashid MU, Seidel-Renkert A, Weitzel JN, Briceno I, Hamann U. Absence of the BRCA1 del (exons 9-12) mutation in breast/ovarian cancer families outside of Mexican Hispanics. Breast Cancer Res Treat 2009; 117(3): 679-81.

  38. Weitzel JN, Lagos VI, Herzog JS, et al. Evidence for common ancestral origin of a recurring BRCA1 genomic rearrangement identified in high-risk Hispanic families. Cancer Epidemiol Biomarkers Prev 2007; 16(8): 1615-20.

  39. Woodson AH, Profato JL, Muse KI, Litton JK. Breast cancer in the young: role of the geneticist. J Thorac Dis 2013; 5(Suppl. 1): S19-S26.

  40. Villarreal-Garza C, Herrera LA, Herzog J, et al. Significant Clinical impact of recurrent BRCA1 and BRCA2 (BRCA) mutations in Mexico. Cancer Research 2012; 72(24 Supplement U). Disponible en: http://cancerres.aacrjournals.org/cgi/content/ meeting_abstract/72/24_MeetingAbstracts/PD08-06):PD08-06.

  41. Villarreal-Garza C, Alvarez-Gomez RM, Perez-Plasencia C, et al. Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico. Cancer. 2014; 120(18): doi 10.1002/ crcr.29058.

  42. Hernandez JE, Llacuachaqui M, Palacio GV, et al. Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Medellin, Colombia. Hered Cancer Clin Pract 2014;12(1):11.

  43. Villarreal-Garza CM, Weitzel JN, Sifuentes E, et al. Founder effect and a high prevalence of BRCA1 mutations among young Mexican triple-negative breast cancer (TNBC) patients. ASCO Meeting Abstracts 2014; 32(15 Suppl U). Disponible en: http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/ 1522):1522.

  44. Fostira F, Tsitlaidou M, Gogas H, et al. Prevalence of BRCA1 mutations among 284 women with triple-negative breast cancer. ASCO Meeting Abstracts 2010; 28(15 suppl U): Disponible en: http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/ 1511):1511.

  45. Gonzalez-Angulo AM, Timms KM, Liu S, et al. Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer. Clin Cancer Res 2011; 17(5): 1082-89.

  46. Young SR, Pilarski RT, Donenberg T, et al. The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. BMC Cancer 2009; 9: 86.

  47. Greenup R, Buchanan A, Lorizio W, et al. Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort. Ann Surg Oncol 2013; 20(10): 3254-8.

  48. Peppercorn J, Partridge AH. Breast cancer in young women: a new color or a different shade of pink? J Clin Oncol 2008; 26(20): 3303-05.

  49. Clark SL, Rodriguez AM, Snyder RR, Hankins GD, Boehning D. Structure-function of the tumor suppressor BRCA1. Comput Struct Biotechnol J 2012; 1(1): 201204005.

  50. Lemieux J, Goodwin PJ, Bordeleau LJ, Lauzier S, Theberge V. Quality-of-life measurement in randomized clinical trials in breast cancer: an updated systematic review (2001-2009). J Natl Cancer Inst 2011; 103(3): 178-231.

  51. Sloan JA, Cella D, Frost M, Guyatt GH, Sprangers M, Symonds T. Assessing clinical significance in measuring oncology patient quality of life: introduction to the symposium, content overview, and definition of terms. Mayo Clin Proc 2002; 77(4): 367-70.

  52. van der Steeg AF, De Vries J, Roukema JA. Quality of life and health status in breast carcinoma. Eur J Surg Oncol 2004; 30(10): 1051-7.

  53. Mor V, Allen S, Malin M. The psychosocial impact of cancer on older versus younger patients and their families. Cancer 1994; 74(7 Suppl.): 2118-27.

  54. Parker PA, Baile WF, de Moor C, Cohen L. Psychosocial and demographic predictors of quality of life in a large sample of cancer patients. Psychooncology 2003; 12(2): 183-93.

  55. Partridge AH. Cancer survivorship and the young breast cancer patient: addressing the important issues. Oncologist 2013; 18(8): e19-e20.

  56. Lee MC, Bhati RS, von Rottenthaler EE, et al. Therapy choices and quality of life in young breast cancer survivors: a shortterm follow-up. Am J Surg 2013; 206(5): 625-31.

  57. Wenzel LB, Fairclough DL, Brady MJ, et al. Age-related differences in the quality of life of breast carcinoma patients after treatment. Cancer 1999; 86(9): 1768-74.

  58. Sammarco A. Quality of life of breast cancer survivors: a comparative study of age cohorts. Cancer Nurs 2009; 32(5): 347- 56; quiz 348-57.

  59. Ganz PA, Goodwin PJ. Health-related quality of life measurement in symptom management trials. J Natl Cancer Inst Monogr 2007(37): 47-52.

  60. Dunn J, Steginga SK. Young women’s experience of breast cancer: defining young and identifying concerns. Psychooncology 2000; 9(2): 137-46.

  61. Wong-Kim EC, Bloom JR. Depression experienced by young women newly diagnosed with breast cancer. Psychooncology 2005; 14(7): 564-73.

  62. Bloom JR, Stewart SL, Johnston M, Banks P, Fobair P. Sources of support and the physical and mental well-being of young women with breast cancer. Soc Sci Med 2001; 53(11): 1513- 24.

  63. Burgess C, Cornelius V, Love S, Graham J, Richards M, Ramirez A. Depression and anxiety in women with early breast cancer: five year observational cohort study. BMJ 2005; 330(7493): 702.

  64. Bifulco G, De Rosa N, Tornesello ML, et al. Quality of life, lifestyle behavior and employment experience: a comparison between young and midlife survivors of gynecology early stage cancers. Gynecol Oncol 2012; 124(3): 444-51.

  65. Howard-Anderson J, Ganz PA, Bower JE, Stanton AL. Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review. J Natl Cancer Inst 2012; 104(5): 386-405.

  66. Rosenberg SM, Tamimi RM, Gelber S, et al. Body image in recently diagnosed young women with early breast cancer. Psychooncology 2013; 22(8): 1849-55.

  67. Burwell SR, Case LD, Kaelin C, Avis NE. Sexual problems in younger women after breast cancer surgery. J Clin Oncol 2006; 24(18): 2815-21.

  68. Hurria A, Somlo G, Ahles T. Renaming “chemobrain”. Cancer Invest 2007; 25(6): 373-7.

  69. Ahles TA, Saykin AJ, McDonald BC, et al. Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Res Treat 2008; 110(1): 143-52.

  70. Castellon SA, Ganz PA, Bower JE, Petersen L, Abraham L, Greendale GA. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol 2004; 26(7): 955-69.

  71. Jenkins V, Shilling V, Deutsch G, et al. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer 2006; 94(6): 828-34.

  72. Ahles TA, Saykin AJ, McDonald BC, et al. Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. J Clin Oncol 2010; 28(29): 4434-40.

  73. Von Ah D, Harvison KW, Monahan PO, et al. Cognitive function in breast cancer survivors compared to healthy age- and education-matched women. Clin Neuropsychol 2009; 23(4): 661-74.

  74. Grau AJ. La sexualidad en pacientes con cáncer: algunas consideraciones sobre su evaluación y tratamiento. Rev Cubana Oncol 1999; 15(1): 49-65.

  75. Krychman ML. Sexual rehabilitation medicine in a female oncology setting. Gynecol Oncol 2006; 101: 380-4.

  76. Stella FM, G.B. O, A. MG. La sexualidad en pacientes con cáncer de mama o cérvix sometidas a tratamiento quirúrgico en el Hospital General, Hospital San Vicente de Paúl e Instituto de Cancerología de la Clínica las Américas. Revista Colombiana de Obstetricia y Ginecología 2002; 5(30): 179-83.

  77. Ganz PA, Kwan L, Stanton AL, et al. Quality of life at the end of primary treatment of breast cancer: first results from the moving beyond cancer randomized trial. J Natl Cancer Inst 2004; 96(5): 376-87.

  78. Schover LR. Sexuality and body image in younger women with breast cancer. J Natl Cancer Inst Monogr 1994(16): 177- 82.

  79. Avis NE, Crawford S, Manuel J. Psychosocial problems among younger women with breast cancer. Psychooncology 2004; 13(5): 295-308.

  80. Stead ML. Sexual dysfunction after treatment for gynaecologic and breast malignancies. Curr Opin Obstet Gynecol 2003; 15(1): 57-61.

  81. Mor V, Malin M, Allen S. Age differences in the psychosocial problems encountered by breast cancer patients. J Natl Cancer Inst Monogr 1994(16): 191-7.

  82. Cain VS, Johannes CB, Avis NE, et al. Sexual functioning and practices in a multi-ethnic study of midlife women: baseline results from SWAN. J Sex Res 2003; 40(3): 266-76.

  83. Partridge AH, Gelber S, Peppercorn J, et al. Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol 2004; 22(20): 4174-83.

  84. Champion VL, Wagner LI, Monahan PO, et al. Comparison of younger and older breast cancer survivors and age-matched controls on specific and overall quality of life domains. Cancer 2014; 120(15): 2237-46.

  85. Rey D, Bouhnik AD, Mancini J, Bendiane MK, Seror V, Viens P. Self-reported cognitive impairment after breast cancer treatment in young women from the ELIPPSE40 cohort: the long-term impact of chemotherapy. Breast J 2012; 18(5): 406-14.

  86. Biller-Andorno N, Juni P. Abolishing mammography screen ing programs? A view from the Swiss Medical Board. N Engl J Med 2014; 370(21): 1965-7.

  87. Pierobon M, Frankenfeld CL. Obesity as a risk factor for triple- negative breast cancers: a systematic review and metaanalysis. Breast Cancer Res Treat 2013; 137(1): 307-14.

  88. Pan H, Gray RG, on behalf of the Early Breast Cancer Trialists’ Collaborative G. Effect of obesity in premenopausal ER+ early breast cancer: EBCTCG data on 80,000 patients in 70 trials. ASCO Meeting Abstracts 2014; 32(15 Suppl. U). Disponible en: http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/ 503):503.

  89. Aguilar JL, Martinez IA, Villarreal-Garza CM, et al. Impact of obesity and overweight in the prognosis of women diagnosed with non metastatic breast cancer in a Mexican cohort. ASCO Meeting Abstracts 2012; 30(15 Suppl. U). Disponible en: http:// meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/ 1607):1607.

  90. Unger-Saldana K. Challenges to the early diagnosis and treatment of breast cancer in developing countries. World J Clin Oncol 2014; 5(3): 465-77.

  91. Liedke PE, Finkelstein DM, Szymonifka J, et al. Outcomes of breast cancer in Brazil related to health care coverage: a retrospective cohort study. Cancer Epidemiol Biomarkers Prev 2014; 23(1): 126-33.

  92. Villarreal-Garza C, Aguila C, Magallanes-Hoyos MC, et al. Breast cancer in young women in Latin America: an unmet, growing burden. Oncologist 2013; 18(Suppl.): 26-34.

  93. Senkus E, Gomez H, Dirix L, et al. Attitudes of young patients with breast cancer toward fertility loss related to adjuvant systemic therapies. EORTC study 10002 BIG 3-98. Psychooncology 2014; 23(2): 173-82




2020     |     www.medigraphic.com